Article Text

Download PDFPDF
UK second-line paediatric primary ITP therapy analysis
  1. Bobby Chaudhury1,2,
  2. John Grainger3
  1. 1 Faculty of Biology Medicine and Health, The University of Manchester, Manchester, UK
  2. 2 University of Manchester Medical School, Manchester, UK
  3. 3 Department of Haematology and Oncology, Royal Manchester Children's Hospital, Manchester, UK
  1. Correspondence to Bobby Chaudhury, The University of Manchester Undergraduate Centre, Manchester Royal Infirmary, The Blvd, Manchester M13 9WG, UK; bobby.chaudhury{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

We analysed the UK pattern of second-line therapy for persistent or chronic primary immune thrombocytopenia (ITP) in children from 2010 to 2019. Patients were considered eligible for therapy if they had a persistent platelet count <30 x 109/L at 6 months after their initial diagnosis.1 Thrombopoietin agonists (TPO-RAs), rituximab, splenectomy and other therapies encompassing azathioprine, chlorphenomine, infliximab, methotrexate, mycophenolate mofetil and cyclosporine were examined. Since 2010, 158 patients out of 1657 children on the UK-Paediatric ITP Registry were eligible, with only 20% receiving intervention.

Data was extracted from the UK Paediatric ITP Registry and divided equidistantly into time periods: 2011–2014 and 2015–2019. Key milestones during this time included the international consensus report on primary ITP management published in 2010,2 the first publication of paediatric Eltrombopag trials and Food and Drug Administration (FDA) approval in 20153 and the Romiplostim clinical trial publications and …

View Full Text


  • Collaborators Nichola Seymour: acquisition and management of data.

  • Contributors BC performed the research, analysed the data and wrote the paper. JG designed the study, analysed the data and wrote the paper.

  • Funding The childhood ITP registry is supported by charitable donation from the ITP Support Association.

  • Competing interests JG: Novartis: honorarium, consultancy; Amgen: honorarium, consultancy; Ono Pharma: consultancy; Alexion: consultancy; Dova Pharmaceutical: consultancy.

  • Provenance and peer review Not commissioned; externally peer reviewed.